This company started in a small office in Thousand Oaks, California in 1980.
At the time, almost nobody outside biotech knew it existed.
When it went public in 1983, $1,000 bought a stake in a company most people couldn’t even pronounce.
That same $1,000 is worth $1.25 million today.
That’s a 18.52% compound annual return over more than four decades.
Through the dot-com crash, the 2008 financial crisis, a global pandemic, and repeated drug trial failures, it kept compounding.
Today it sits in the Dow Jones 30, generates $36.75B in annual revenue, and has multiple products still growing at double-digit rates.
It is still trading below its all-time high, with analysts pricing it roughly 30% higher than current levels.
Guess the ticker.